'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
“Moderna在與輝瑞和BioNTech就Covid疫苗的專利糾紛中勝訴；該決定爲這家mRNA疫苗製造商爲從競爭對手那裏收回大流行利潤而進行的法律鬥爭中是一個福音”-《金融時報》
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandemic profits from its rivals.
Moderna在歐洲專利局與輝瑞和BioNTech就其Covid-19疫苗發生的糾紛中勝訴，這對於這家mRNA疫苗生產商爲從競爭對手那裏收回大流行利潤而進行的持續法律鬥爭帶來了福音。
The decision by the EPO's Opposition Division on Thursday to uphold the validity of one of two disputed patents is a boost for Moderna, which has faced several setbacks in its legal battle over Pfizer and BioNTech's bestselling Comirnaty vaccine.
歐洲專利局反對部週四決定維持兩項有爭議專利之一的有效性，這對Moderna來說是一個推動力。Moderna在爭奪輝瑞和BioNTech最暢銷的Comirnaty疫苗的法律鬥爭中遇到了幾次挫折。
"We are pleased to announce that the European Patent Office decided to maintain the validity of Moderna...
該公司告訴《金融時報》：“我們很高...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。